BrainAge moderates associations between AD biomarkers and cognitive decline: findings from A4/LEARN and the Harvard Aging Brain Study

BrainAge<sub>delta</sub> is significantly associated with Aβ and tau burden and moderates their association with cognitive decline, supporting previous literature suggesting that BrainAge is a robust marker of brain health. Prioritizing individuals with worse BrainAge for clinical trials could not only effectively reduce screen fails (estimates forthcoming) but is a potentially feasible approach given that it can be calculated from a single T1-weighted MRI scan. These findings also highlight the importance of age-independent neurodegeneration patterns to contribute unique signal in models of brain health and pathological progression.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70862_109903
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

BrainAge moderates associations between AD biomarkers and cognitive decline: findings from A4/LEARN and the Harvard Aging Brain Study

Aaron P. Schultz, Timothy J. Hohman, Michael Donohue, Rachel F. Buckley et al.
Alzheimer s & Dementia
Dementia and Cognitive Impairment Research
article

BrainAge moderates associations between AD biomarkers and cognitive decline: findings from A4/LEARN and the Harvard Aging Brain Study

Aaron P. Schultz, Timothy J. Hohman, Michael Donohue, Rachel F. Buckley, Ibai Díez, Jorge García Condado, Gillian Coughlan, Colin Birkenbihl, Asier Erramuzpe, D. Rentz, Jasmeer P. Chhatwal, Hannah M Klinger, Cortes Jesús, R. A. Sperling, Hyun‐Sik Yang, Iñigo Tellaetxe Elorriaga, Keith A. Johnson, Michael J. Properzi, Mabel Seto
article en

Abstract

BrainAge<sub>delta</sub> is significantly associated with Aβ and tau burden and moderates their association with cognitive decline, supporting previous literature suggesting that BrainAge is a robust marker of brain health. Prioritizing individuals with worse BrainAge for clinical trials could not only effectively reduce screen fails (estimates forthcoming) but is a potentially feasible approach given that it can be calculated from a single T1-weighted MRI scan. These findings also highlight the importance of age-independent neurodegeneration patterns to contribute unique signal in models of brain health and pathological progression.

Alzheimer s & DementiaVol. 21(S8)
Ikerbasque (ES), University of Southern California (US), Brigham and Women's Hospital (US), Harvard University (US), The University of Melbourne (AU), University of the Basque Country (ES), Vanderbilt University (US), Massachusetts General Hospital (US), BioCruces Health research Institute (ES), Euskadiko Parke Teknologikoa (ES)
Quality Education
Openalex Percentile: Top 36%
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.